Evidence map›Paper›PMID 36841638›Full record

ArticleHeart, lung & circulation2023

Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinations-A Single-Centre Retrospective Analysis.

Marina Wassif, Phillip Lo, Paul Satouris, Lucinda Swan, Daniel Tardo, Jason C Kovacic, David Muller, Kavitha Muthiah, Eugene Kotlyar, Nicole K Bart

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart, lung & circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Marina WassifDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia. Electronic address: marina.wassif@health.nsw.gov.au.
Phillip LoDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Paul SatourisDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia.
Lucinda SwanDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia.
Daniel TardoDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia.
Jason C KovacicDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David MullerDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Kavitha MuthiahDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Eugene KotlyarDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia.
Nicole K BartDepartment of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia.
Victor Chang Cardiac Research Institute · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the rapid rollout of COVID-19 vaccinations, numerous associated and suspected adverse events have been reported nationally and worldwide. Literature reporting confirmed cases of pericarditis and myocarditis following SARS-CoV-2 mRNA vaccinations has evolved, with a predominance in adolescent males following the second dose.

methodsThis was a retrospective analysis of all patients presenting to St Vincent's Hospital, Sydney, Australia with suspected COVID-19 vaccine-related myocarditis and pericarditis. The Brighton Collaboration Case Definitions of Myocarditis and Pericarditis were used to categorise patients into groups based on diagnostic certainty. Cardiac magnetic resonance imaging findings were reviewed against updated Lake Louise Criteria for diagnosing patients with suspected myocarditis.

resultsWe report 10 cases of confirmed, possible or probable myocarditis and pericarditis. The mean age of presentation in the vaccine group was 33±9.0 years. The most common presenting symptom was pleuritic chest pain (n=8, 80%). Eight patients (80%) had electrocardiogram (ECG) abnormalities (n=6 pericarditis, n=2 myocarditis). Five patients (50%) had a minimum 24 hours of cardiac monitoring. One patient had multisystem inflammatory syndrome following vaccination (MIS-V) with severely impaired left ventricular ejection fraction and required admission to the intensive care unit. DISCUSSION AND

conclusionCardiac complications post mRNA vaccines are rare. Our case series reflects the worldwide data that vaccine-related myocarditis and pericarditis most frequently occur in young males, following the second dose of the vaccine. These cardiac side effects are mild and self-limiting, with adequate responses to oral anti-inflammatories. One patient developed a severe reaction, with no fatal cases.

Indexed as

COVID-19COVID-19 VaccinesMyocarditisPericarditisAdultHumansRetrospective StudiesStroke VolumeVaccinationVentricular Function, LeftYoung AdultCOVID-19 VaccinesmRNA COVID vaccinationMultisystem inflammatory syndrome following vaccination (MIS-V)MyocarditisPericarditis

Identifiers

PMID36841638
PMCPMC9951393
OpenAlexW4321793294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.